Clare Jonas's blog posts
Supporter stories Bloodwise research highlights 2018
It’s been a great year in blood cancer research, from CAR-T therapy to a new understanding of how leukaemia develops in children. We take a look back at some of the breakthroughs our supporters have helped to fund in 2018.
Supporter stories Successful stem cell transplants without chemotherapy or radiotherapy?
One option for treating or even curing blood cancers – especially those which have relapsed, or are resistant to other treatments – is a stem cell transplant, but this procedure can be gruelling because it requires radiotherapy or chemotherapy to destroy existing stem cells before new ones can be given. What if there was a less toxic way to get rid of these stem cells? Dr Adam Wilkinson, Bloodwise Visiting Fellow at Stanford University in the USA, may have found one…
Supporter stories How does the immune system recognise and destroy Hodgkin lymphoma?
In Hodgkin lymphoma, the cells which are the root cause of the cancer are hidden within a much larger number of white blood cells. These white blood cells are usually very good at killing cancer cells, but may be unable to kill all of the Hodgkin lymphoma cells. Bloodwise Visiting Fellow Dr Zumla Cader has been investigating why...
Supporter stories Why can it take so long to diagnose myeloma?
At the University of York, Dr Debra Howell and other members of the Haematological Malignancy Research Network (HMRN), funded by Bloodwise, have been asking people with myeloma to talk about their experiences from when they first felt ill to their diagnosis, to better understand the possible events that could happen during this time. Below, you can read a summary of this work.
Supporter stories Through the eye of a needle: Molecular immunology and anti-cancer drugs
Finding drugs that can target cancer cells but leave healthy cells unharmed is an ongoing problem in cancer research. At the University of Oxford, Professor Terry Rabbitts is exploring ways to create targeted drugs that work by blocking blood cancer proteins from interacting with healthy proteins – and the technique he’s developed for making these drugs could also have an impact on many other diseases. Read on to find out more…
Supporter stories How myeloproliferative neoplasms disrupt the work of blood stem cells
Blood stem cells need to strike a delicate balance between making other types of blood cells and renewing themselves. When myeloproliferative neoplasms happen, this balance is disrupted. Recent research carried out by Bloodwise-funded researchers at the University of Cambridge has revealed the genetic changes that cause these disruptions.